Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H32N6O5S |
| Molecular Weight | 504.602 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=NN(C)C2=C1N=C(NC2=O)C3=CC(=CC=C3OCC)S(=O)(=O)N4CCN(CCO)CC4
InChI
InChIKey=NEYKRKVLEWKOBI-UHFFFAOYSA-N
InChI=1S/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31)
| Molecular Formula | C23H32N6O5S |
| Molecular Weight | 504.602 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lodenafil carbonate, a novel phosphodiesterase 5 inhibitor developed in Brazil. Lodenafil carbonate is a prodrug that is metabolized with formation of the active compound, lodenafil. Lodenafil carbonate participated in phase III clinical trial for erectile dysfunction and showed a satisfactory efficacy-safety profile.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. | 2008 Sep 4 |
|
| Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. | 2010 Feb |
|
| Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. | 2010 May |
|
| Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats. | 2014 Jul-Aug |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:35:21 UTC 2023
by
admin
on
Sat Dec 16 08:35:21 UTC 2023
|
| Record UNII |
80X7B1F6NW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Lodenafil
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60161161
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
PRIMARY | |||
|
139755-85-4
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
PRIMARY | |||
|
LODENAFIL
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
PRIMARY | |||
|
80X7B1F6NW
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
PRIMARY | |||
|
135452901
Created by
admin on Sat Dec 16 08:35:21 UTC 2023 , Edited by admin on Sat Dec 16 08:35:21 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
